


### Amendments to the Claims

Please amend the listing of claims as follows:

1. (Original) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms and a pharmaceutically acceptable excipient.
2. (Original) A pharmaceutical composition in accordance with claim 1, wherein said compound has a first gold(I) atom covalently bonded to a first carbon atom and a second gold(I) atom covalently bonded to a second carbon atom.
3. (Original) A pharmaceutical composition in accordance with claim 2, wherein said compound comprises a substituted or unsubstituted aromatic group as part of the covalent link.
4. (Currently Amended) A pharmaceutical composition in accordance with claim 2 ~~or 3~~, wherein the first carbon atom is part of a substituted or unsubstituted aromatic group.
5. (Original) A pharmaceutical composition in accordance with claim 4, wherein the substituted or unsubstituted aromatic group is a substituted or unsubstituted phenyl group.
6. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 2 ~~to 5~~, wherein the second carbon atom is part of a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group.
7. (Original) A pharmaceutical composition in accordance with claim 6, wherein the aromatic group of which the second carbon atom is a part is a substituted or unsubstituted phenyl group.
8. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 2 ~~to 7~~, wherein said compound incorporates a moiety having the formula:



where: Au<sup>1</sup> is said first gold (I) atom; Au<sup>2</sup> is said second gold (I) atom; C<sup>1</sup> is said first carbon atom; C<sup>2</sup> is said second carbon atom; Z is a linking group; and n is 0 or 1.


9. (Currently Amended) A pharmaceutical composition in accordance with ~~any preceding claim~~ claim 1, wherein said compound comprises a ligand bonded to each of said gold(I) atoms, each of said ligands being individually selected from the group consisting of PR<sub>3</sub>, P(OR)<sub>3</sub>, CNR, NCR, PR<sub>n</sub>(CH<sub>2</sub>OR<sup>†</sup>)<sub>3-n</sub>, N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>, [N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, PN<sub>3</sub>C<sub>6</sub>H<sub>12</sub>, and P[N<sub>3</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, where R is a substituted or unsubstituted hydrocarbon moiety and R<sup>†</sup> is selected from the group consisting of H, Me, SO<sub>2</sub><sup>-</sup>, PO<sub>3</sub><sup>-</sup>, alkyl and aryl, and each R<sup>†</sup> in any one ligand is the same or different.

10. (Original) A pharmaceutical composition in accordance with claim 9, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.

11. (Currently Amended) A pharmaceutical composition in accordance with claim 9-~~or 10~~, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.


12. (Currently Amended) A pharmaceutical composition in accordance with claim 9,~~10 or 11~~, wherein the ligand is PPh<sub>3</sub>.

13. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of claims 1 to 7~~, wherein said compound has the formula:




where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO<sub>3</sub><sup>-</sup>, PO<sub>4</sub><sup>2-</sup>, CO<sub>2</sub>H, OH, (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR''''C(O)(R''''') where R'''' and R''''' are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6.

14. (Original) A pharmaceutical composition in accordance with claim 13, wherein said compound has a formula selected from the group consisting of:




15. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1 ~~to~~ 7, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO<sub>3</sub><sup>-</sup>, PO<sub>4</sub><sup>2-</sup>, CO<sub>2</sub>H, OH, (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR''''C(O)(R''''') where R'''' and R''''' are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6.


16. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1 to 7, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO<sub>3</sub><sup>-</sup>, PO<sub>4</sub><sup>2-</sup>, CO<sub>2</sub>H, OH, (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR''''C(O)(R''''') where R'''' and R''''' are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6; and X is a linking group.


17. (Original) A pharmaceutical composition in accordance with claim 16, wherein X is selected from the group consisting of: O, S, PR or NR in which R is a substituted or unsubstituted hydrocarbon moiety.

18. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1 to 7, wherein said compound has the formula:




where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO<sub>3</sub><sup>-</sup>, PO<sub>4</sub><sup>2-</sup>, CO<sub>2</sub>H, OH, (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR''''C(O)(R''''') where R'''' and R''''' are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6.

19. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1 ~~to~~ 7, wherein said compound has the formula:



Where Y is selected from the group consisting of  $(R')_bAuL'$  and



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H,  $SO_3^-$ ,  $PO_4^{2-}$ ,  $CO_2H$ , OH,  $(CH_2)_nCH_3$ ,  $O(CH_2)_nCH_3$ ,  $S(CH_2)_nCH_3$ , or  $NR''''C(O)(R''''')$  where R'''' and R'''' are  $(CH_2)_nCH_3$ ; and n is 0 to 6.

20. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 13 ~~to~~ 19, wherein L and L' are independently selected from the group consisting of  $PR_3$ ,  $P(OR)_3$ , CNR, NCR,  $PR_n(CH_2OR^\dagger)_{3-n}$ ,  $N_4C_6H_{12}$ ,  $[N_4C_6H_{12}-N-CH_3]^+$ ,  $PN_3C_6H_{12}$ , and  $P[N_3C_6H_{12}-N-CH_3]^+$ , where R is a substituted or unsubstituted hydrocarbon moiety and  $R^\dagger$  is selected from the group consisting of H, Me,  $SO_2^-$ ,  $PO_3^-$ , alkyl and aryl, and each  $R^\dagger$  in any one ligand is the same or different.

21. (Original) A pharmaceutical composition in accordance with claim 20, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.

22. (Currently Amended) A pharmaceutical composition in accordance with claim 20 ~~or~~ 21, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.

23. (Currently Amended) A pharmaceutical composition in accordance with claim 20, ~~21 or 22~~, wherein the ligand is PPh<sub>3</sub>.

24. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 13 ~~to 23~~, wherein R' and R'' are each independently selected from the group consisting of methylene, ethylene, propylene, butylene and phenylene groups.

25. (Original) A compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms for use as a chemotherapeutic agent.

26.-30. (Canceled)

31. (Original) A method of treating a cancer in a human or animal patient comprising administering to said patient a therapeutically effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms.

32. (Original) A method in accordance with claim 31, wherein the cancer is resistant to a platinum drug.

33. (Original) A method in accordance with claim 32, wherein the cancer is resistant to cisplatinum and/or carboplatinum.

34. (Currently Amended) A method in accordance with claim 31, ~~32 or 33~~, wherein the cancer is ovarian or lung cancer.

35. (Canceled)

36. (Original) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having a first gold atom which is a gold(III) atom and a second gold atom which is either a gold(I) atom or a gold(III) atom, each of said first and second gold atoms being covalently bonded to a carbon atom in a covalent link connecting the first and second gold atoms, and the or each gold(III) atom being reducible, *in vivo*, to a gold(I) atom, and a pharmaceutically acceptable excipient.

37. (Original) A pharmaceutical composition in accordance with claim 36, wherein said second gold atom is a gold(III) atom.

38. (Original) A compound having a first gold atom which is a gold(III) atom and a second gold atom which is either a gold(I) atom or a gold(III) atom, each of said first and second gold atoms being covalently bonded to a carbon atom in a covalent link connecting the first and second gold atoms, and the or each gold(III) atom being reducible, *in vivo*, to a gold(I) atom for use as a chemotherapeutic agent.

39. (Canceled)

40. (Original) A method of treating a cancer in a human or animal patient comprising administering to said patient a therapeutically effective amount of a compound having a first gold atom which is a gold(III) atom and a second gold atom which is either a gold(I) atom or a gold(III) atom, each of said first and second gold atoms being covalently bonded to a carbon atom in a covalent link connecting the first and second gold atoms, and the or each gold(III) atom being reducible, *in vivo*, to a gold(I) atom.